The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Orforglipron, a daily GLP-1 receptor agonist pill, lowered HbA1c by up to 1.6% and body weight by 7.9% in a phase III trial ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...